A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
Disruptive Behavior Disorder
About this trial
This is an interventional treatment trial for Disruptive Behavior Disorder focused on measuring Disruptive behavior disorder, risperidone, antipsychotropic agents, child, adolescent
Eligibility Criteria
Inclusion Criteria: Patients must have completed the double-blind study (CR002020) Patients must begin the present study within 7 days of taking the last dose of medication in the prior study (CR002020) Exclusion Criteria: Patients with hypersensitivity or intolerance to risperidone Patients with extrapyramidal symptoms (EPS) not adequately controlled with medication History of neuroleptic malignant syndrome, a rare psychotropic-drug reaction, which may be characterized by confusion, reduced consciousness, high fever or pronounced muscle stiffness Significant and untreated or unstable medical illness such as diabetes, hypertension serious illness of the liver, kidney, or significant disturbances of the cardiac, pulmonary, gastrointestinal, endocrine, neurological system Pregnant or nursing females, or those lacking adequate contraception